Timolol maleate

ApprovedSmall molecule

AAuson Pharmaceuticals Inc.

Timolol maleate is one of 109 small molecule programs targeting Hemangioma. It is currently in Approved.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemangiomaActive, not recruiting

GlaucomaActive, not recruiting

Ocular HypertensionActive, not recruiting

Esophageal VaricesActive, not recruiting

NeuropathyActive, not recruiting

HemangiomaPreclinical

Active, not recruiting

GlaucomaApproved

Active, not recruiting

Ocular HypertensionPhase 1/Phase 2

Active, not recruiting

Esophageal VaricesPhase 3

Active, not recruiting

NeuropathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Timolol maleate

AAuson Pharmaceuticals Inc.

Approved

5 2

Alphagan

Novartis

Phase 3

1 3

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

9 4

Azopt

Novartis

Phase 3

1 5

Ocupress

AbbVie

Phase 3

1 6

LUMIGAN

AbbVie

Phase 3

2 7

Krytantek

AbbVie

Phase 3

2 8

Bimatoprost/timolol

AbbVie

Phase 3

4 9

Preservative-Free Tafluprost

Merck & Co.

Phase 3

2 10

Combigan

EEMS

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ARecruiting

Hemangioma

NCT01873131

Clinical

Trials by Indication[1]

Ocular Hypertension5 trials

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Completed·BBausch & Lomb Incorporated·Phase 2·NCT01707381·25 enrolled

A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

Completed·VVistakon Pharmaceuticals··NCT00823043·103 enrolled

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

Completed·QQlaris Bio, Inc.·Phase 2·NCT04830397·84 enrolled

Show 2 more trials

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

Completed·OOthera Pharmaceuticals·Phase 1/2·NCT00753168·48 enrolled

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

Completed·SSanten Inc.·Phase 1/2·NCT01279083·147 enrolled

Hemangioma2 trials

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn

Recruiting·MMassachusetts General Hospital·N/A·NCT01873131·126 enrolled

Timolol Maleate Gel for the Treatment of Infantile Hemangioma

Completed·AAuson Pharmaceuticals Inc.·Phase 2/3·NCT06677853·168 enrolled

Esophageal Varices1 trial

Prevention of Esophageal Varices by Beta-Adrenergic Blockers

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00006398·213 enrolled

ESS1 trial

Assessing Cosopt Switch Patients

Completed·PPharmaceutical Research Network·Phase 4·NCT00273442·60 enrolled

Neuropathy1 trial

Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%

Withdrawn·FFraser Health·Phase 1·NCT01607671

6 more indications

Interaction1 trial

Interaction Study of Timolol Eye Drops and Paroxetine Capsules

Completed·SSanten Oy·Phase 1·NCT00879099·12 enrolled

Glaucoma1 trial

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study

Completed·WWills Eye·Phase 4·NCT03323164·35 enrolled

Chronic Wounds1 trial

Absorption and Safety of Topical Timolol to Treat Chronic Wounds

Completed·VVA Northern California Health Care System··NCT04903366·40 enrolled

Tolerance1 trial

Evaluate the Safety, Tolerance, and Pharmacokinetic Profiles of Timolol Maleate Gel

Completed·AAuson Pharmaceuticals Inc.·Phase 1·NCT06824948·28 enrolled

Anti-angiogenic Therapy1 trial

Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept

Completed·UUnity Health Toronto·Phase 1/2·NCT01752049·5 enrolled

Extremity1 trial

Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT06941467·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Timolol maleate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Timolol maleate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Timolol maleate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Auson Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAuson Pharmaceuticals Inc.

Timolol maleate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Ocular Hypertension5 trials

Hemangioma2 trials

Esophageal Varices1 trial

ESS1 trial

Neuropathy1 trial

Interaction1 trial

Glaucoma1 trial

Chronic Wounds1 trial

Tolerance1 trial

Anti-angiogenic Therapy1 trial

Extremity1 trial

References

Drug Info

Quick Facts

Related News